Validation Data Gallery
Tested Applications
| Positive FC detected in | Anti-CD3/CD28 treated mouse splenocytes |
Recommended dilution
| Application | Dilution |
|---|---|
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| FC | See 2 publications below |
Product Information
PE-65073 targets PD-L1/CD274 in FC applications and shows reactivity with mouse samples.
| Tested Reactivity | mouse |
| Cited Reactivity | mouse |
| Host / Isotype | Rat / IgG2b, kappa |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen | N/A 相同性解析による交差性が予測される生物種 |
| Full Name | CD274 antigen |
| GenBank accession number | BC066841 |
| Gene Symbol | PD-L1 |
| Gene ID (NCBI) | 60533 |
| RRID | AB_2883870 |
| Conjugate | PE Fluorescent Dye |
| Excitation/Emission maxima wavelengths | 496 nm, 565 nm / 578 nm |
| Form | Liquid |
| Purification Method | Affinity purification |
| UNIPROT ID | Q9EP73 |
| Storage Buffer | PBS with 0.09% sodium azide , pH 7.3 |
| Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
Programmed cell death ligand 1 (PD-L1, CD274, or B7-H1), is the first member of B7 family to be discovered. B7 family molecules are type I transmembrane proteins belonging to the immunoglobulin superfamily. In concert with their CD28 family receptors, the B7s are key regulators of the adaptive immune response. PD-L1 is suggested as a negative regulator of T and B cell, and plays important role in mediating tolerance of lymphocytes to self-antigens. It is also involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PD-1-independent manner.
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for PE PD-L1/CD274 antibody PE-65073 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Biochem Pharmacol Targeting HMGA1 contributes to immunotherapy in aggressive breast cancer while suppressing EMT | ||